Neisseria meningitidis, Serogroup A
"Neisseria meningitidis, Serogroup A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Strains of Neisseria meningitidis responsible for most outbreaks of meningococcal disease in Western Europe and the United States in the first half of the 20th century. They continue to be a major cause of disease in Asia and Africa, and especially localized epidemics in Sub-Sahara Africa.
MeSH Number(s)
B03.440.400.425.550.550.641.700
B03.660.075.525.520.500.700
Below are MeSH descriptors whose meaning is more general than "Neisseria meningitidis, Serogroup A".
Below are MeSH descriptors whose meaning is more specific than "Neisseria meningitidis, Serogroup A".
This graph shows the total number of publications written about "Neisseria meningitidis, Serogroup A" by people in Harvard Catalyst Profiles by year, and whether "Neisseria meningitidis, Serogroup A" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
Below are the most recent publications written about "Neisseria meningitidis, Serogroup A" by people in Profiles.
-
Serogroup A meningococcal conjugate vaccines: building sustainable and equitable vaccine strategies. Expert Rev Vaccines. 2020 05; 19(5):455-463.
-
Vaccines and global health: In search of a sustainable model for vaccine development and delivery. Sci Transl Med. 2019 06 19; 11(497).
-
Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in Previously Immunized HIV-Infected Children and Youth. J Pediatric Infect Dis Soc. 2017 Sep 01; 6(3):e69-e74.
-
Human Complement Bactericidal Responses to a Group A Meningococcal Conjugate Vaccine in Africans and Comparison to Responses Measured by 2 Other Group A Immunoassays. Clin Infect Dis. 2015 Nov 15; 61 Suppl 5:S554-62.
-
Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2012 Jan; 31(1):47-52.
-
Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. Pediatr Infect Dis J. 2010 May; 29(5):391-6.